Ulf Wiinberg

CIK: 0001187314

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)12 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

INKT

MiNK Therapeutics, Inc.

Director

AGEN

AGENUS INC

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

INKT
MiNK Therapeutics, Inc.
Sep 1, 2026
Award(A)
Direct
1.3K shares at avg. $10.95$14K
INKT
MiNK Therapeutics, Inc.
Jun 1, 2026
Award(A)
Direct
1.1K shares at avg. $12.38$14K
INKT
MiNK Therapeutics, Inc.
Mar 2, 2026
Award(A)
Direct
1.3K shares at avg. $10.90$14K
INKT
MiNK Therapeutics, Inc.
Jan 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
5.4K shares-
INKT
MiNK Therapeutics, Inc.
Dec 1, 2025
Award(A)
Direct
1.3K shares at avg. $11.09$14K
INKT
MiNK Therapeutics, Inc.
Sep 9, 2025
Award(A)
Stock Option (Right to Buy)
Direct
3.2K shares-
INKT
MiNK Therapeutics, Inc.
Sep 2, 2025
Award(A)
Direct
1K shares at avg. $13.86$14K
INKT
MiNK Therapeutics, Inc.
Jun 2, 2025
Award(A)
Direct
2K shares at avg. $7.17$14K
INKT
MiNK Therapeutics, Inc.
Mar 3, 2025
Award(A)
Direct
1.6K shares at avg. $8.79$14K
INKT
MiNK Therapeutics, Inc.
Dec 1, 2024
Award(A)
Direct
20.5K shares at avg. $0.73$15K
AGEN
AGENUS INC
Oct 1, 2024
Award(A)
Deferred Stock Units
Direct
3.4K shares-
INKT
MiNK Therapeutics, Inc.
Sep 3, 2024
Award(A)
Direct
18.3K shares at avg. $0.82$15K

		Type	Shares	Price		Ownership
Sep 1, 2026	INKT MiNK Therapeutics, Inc.	Award(A)	1,279	$10.95	$14,005	Direct
Jun 1, 2026	INKT MiNK Therapeutics, Inc.	Award(A)	1,131	$12.38	$14,002	Direct
Mar 2, 2026	INKT MiNK Therapeutics, Inc.	Award(A)	1,285	$10.90	$14,007	Direct
Jan 2, 2026	INKT MiNK Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	5,395	-	-	Direct
Dec 1, 2025	INKT MiNK Therapeutics, Inc.	Award(A)	1,263	$11.09	$14,007	Direct
Sep 9, 2025	INKT MiNK Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	3,225	-	-	Direct
Sep 2, 2025	INKT MiNK Therapeutics, Inc.	Award(A)	1,011	$13.86	$14,012	Direct
Jun 2, 2025	INKT MiNK Therapeutics, Inc.	Award(A)	1,953	$7.17	$14,003	Direct
Mar 3, 2025	INKT MiNK Therapeutics, Inc.	Award(A)	1,593	$8.79	$14,002	Direct
Dec 1, 2024	INKT MiNK Therapeutics, Inc.	Award(A)	20,476	$0.73	$14,947	Direct
Oct 1, 2024	AGEN AGENUS INC	Award(A) Deferred Stock Units	3,423	-	-	Direct
Sep 3, 2024	INKT MiNK Therapeutics, Inc.	Award(A)	18,295	$0.82	$15,002	Direct

1-12 of 12 transactions

About WIINBERG ULF

WIINBERG ULF (SEC CIK 0001187314) files insider reports with the SEC as Director of MiNK Therapeutics, Inc. (INKT) and Director of AGENUS INC (AGEN).

Signal8 holds 11 ownership filings by WIINBERG ULF, all Form 4s, filed between Sep 5, 2024 and Sep 2, 2026. Those filings report 12 transactions, from Sep 3, 2024 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on WIINBERG ULF's filings is in NEW YORK, NY.

Recent filings by WIINBERG ULF

Sep 1, 2026: Grant or award of INKT shares (Form 4, code A).
Jun 1, 2026: Grant or award of INKT shares (Form 4, code A).
Mar 2, 2026: Grant or award of INKT shares (Form 4, code A).
Jan 2, 2026: Grant or award of INKT derivative securities (Form 4, code A).
Dec 1, 2025: Grant or award of INKT shares (Form 4, code A).

Other insiders filing for MiNK Therapeutics, Inc. (INKT)

Buell Jennifer, Chief Executive Officer
Holcomb John Bradley, Director
Behner Peter, Director
Ryan Barbara, Director
Corvese Brian, Director
Orilall Melissa, Principal Financial Officer

How to read Form 4 transaction codes